An extremely important step in the treatment of multiple myeloma and lymphomas is the adequate mobilization of HSC, as this is essential for obtaining a sufficient number of CD34+ cells needed for auto-HSCT. This evidence concerns the gene CD34 and plasma cell myeloma.